4 Analysts Have This To Say About TransMedics Group

Throughout the last three months, 4 analysts have evaluated TransMedics Group TMDX, offering a diverse set of opinions from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $116.0, with a high estimate of $130.00 and a low estimate of $104.00. Observing a 9.43% increase, the current average has risen from the previous average price target of $106.00.

Interpreting Analyst Ratings: A Closer Look

The analysis of recent analyst actions sheds light on the perception of TransMedics Group by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to TransMedics Group. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of TransMedics Group compared to the broader market.
• Price Targets: Analysts provide insights into price targets, offering estimates for the future value of TransMedics Group's stock. This comparison reveals trends in analysts' expectations over time.

Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of TransMedics Group's market position. Stay informed and make well-informed decisions with our Ratings Table.

Stay up to date on TransMedics Group analyst ratings.

About TransMedics Group

TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.

TransMedics Group: A Financial Overview

Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: TransMedics Group's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 48.21%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: TransMedics Group's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 17.89% net margin, the company effectively manages costs and achieves strong profitability.

Return on Equity (ROE): TransMedics Group's ROE excels beyond industry benchmarks, reaching 10.38%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): TransMedics Group's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.13%, the company showcases efficient use of assets and strong financial health.

Debt Management: TransMedics Group's debt-to-equity ratio surpasses industry norms, standing at 1.95. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

The Significance of Analyst Ratings Explained

Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.

In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.